Executive summary: US Drug Patent 7,619,004 claims a specific dose-reduction method for colchicine prophylaxis of gout flares in humans who receive concomitant clarithromycin, defined by (i) a 75% colchicine dose reduction versus a baseline colchicine prophylactic dose used when clarithromycin is absent, (ii) a timing window for clarithromycin relative to colchicine (clarithromycin given within 1 to 2 days of the reduced colchicine dosing), and (iii) explicit exemplified daily dose levels: 0.3 mg/day (from 1.2 mg/day baseline) or 0.15 mg/day (from 0.6 mg/day baseline, including every-other-day dosing). Dependent claims narrow to adult status, age ranges, tablet dosing units (0.6 mg tablet or half tablet), and a “concurrently administered” clarithromycin construct. The landscape implication is that the enforceable core is not “colchicine prophylaxis in general,” but colchicine prophylaxis paired with clarithromycin under a dose and timing regime designed to mitigate colchicine toxicity.

US Patent 7,619,004 Claims Scope: Colchicine Prophylaxis With Clarithromycin Via 75% Dose Reduction

US 7,619,004 is drafted as a method-of-use patent. The claim set is dominated by a single treatment logic: reduce colchicine exposure by a defined fraction when clarithromycin is used closely in time, where the reduction is 75% and the “baseline” daily dose is explicitly tied to particular prophylactic dosing amounts.

What is the core claim scope of US 7,619,004 for colchicine prophylaxis with clarithromycin?

Core independent claim 1 covers a prophylactic method that requires all of the following elements:

Indication and patient setting
- Using colchicine for prophylactic treatment of gout flares in a human gout patient.
Risk mitigation mechanism
- The method is intended “so as to reduce the occurrence of colchicine toxicity” when the patient is receiving concomitant clarithromycin.
Dose-reduction parameter
- “Orally administering a second colchicine daily dosage amount” that is a 75% reduction of a first colchicine daily dosage amount that is “suitable for daily oral administration” when clarithromycin is not given.
Timing requirement
- “Concomitant administration of clarithromycin” is defined as clarithromycin administration occurring within 1 to 2 days of orally administering the reduced (second) colchicine dosage amount.
Explicit baseline and reduced dose alternatives Claim 1 includes multiple dose “or” options, each with explicit numbers:
- Option A:
  - Baseline: 1.2 mg/day, as two 0.6 mg doses per day
  - Reduced: 0.3 mg/day
- Option B:
  - Baseline: 0.6 mg/day
  - Reduced: 0.15 mg/day, administered as 0.3 mg every other day
- Option C:
  - Baseline: 0.6 mg/day
  - Reduced: 0.15 mg/day (stated as a daily amount)

Claim 1 is therefore “closed-form” on dosing and timing. A method that uses clarithromycin but reduces colchicine by anything other than 75% or outside the 1 to 2 day relative timing window will typically fall outside literal coverage.

How do the claim’s dosage alternatives shape infringement risk?

The three dosage alternatives in claim 1 create separate literal pathways. If a patient is managed such that the reduced regimen matches any one pathway, literal infringement is more plausible.

Claim 1 dosing alternative	Baseline colchicine prophylaxis (no clarithromycin)	Reduced colchicine daily dose with clarithromycin	How the reduced dose can be administered (as written)
Option A	1.2 mg/day (two 0.6 mg doses/day)	0.3 mg/day	Implicitly oral dosing to achieve 0.3 mg/day
Option B	0.6 mg/day	0.15 mg/day	“administered as 0.3 mg every other day”
Option C	0.6 mg/day	0.15 mg/day	Explicitly includes 0.15 mg/day statement

What do dependent claims add to scope and who do they cover?

Dependent claims 2–4 and 5–8 narrow claim coverage by specifying dose unit form, age, adult status, and clarithromycin timing phrasing.

How does claim 2 limit the colchicine dose form (tablet/half-tablet)?

Claim 2: “The method of claim 1 wherein the patient is administered each dose of colchicine as one 0.6 mg colchicine tablet or as one half of a 0.6 mg colchicine tablet.”

This is an additional literal constraint on administration form. If a competitor uses different dosage forms (for example, liquid formulations, compounded dosing that does not correspond to 0.6 mg tablet or half-tablet units, or different strength tablets) they may attempt to avoid this dependent-claim limitation, though they could still be argued to infringe independent claim 1 depending on how courts interpret “each dose” and equivalence.

What does claim 3 require about patient population?

Claim 3 restricts to an adult human gout patient.

What does claim 4 do about age cutoffs?

Claim 4 further narrows: adult patient less than 70 years old.

This is significant because claim 1 is not limited to age. Dependent claims 3 and 4 create extra protection for certain demographics, but enforceability against pediatric or older cohorts would likely rely on claim 1 (not dependent claims 3–4).

How does claim 5 restate the method using “manufacturers’ recommended” baseline dosing?

Claim 5 is a second independent claim (or separate independent-style claim) focusing on:

“administering a reduced colchicine daily dosage amount”
reduced amount is 75% of a manufacturers’ recommended colchicine daily dosage amount for gout flare prophylaxis in the absence of concomitant clarithromycin
clarithromycin defined as administration within 1 to 2 days of orally administering the reduced colchicine dosage amount
patient is an adult human gout patient

This claim changes the baseline anchor from “first dosage amount suitable for daily oral administration” (claim 1) to a baseline anchored to “manufacturers’ recommended” daily dosing.

Why the “manufacturers’ recommended” phrasing matters

The baseline dose becomes tied to external reference dosing. That can broaden evidence-based argumentation in litigation by pointing to the colchicine label or a manufacturer dosing recommendation. It can also create defense opportunities if the baseline dosing reference differs across jurisdictions/eras or between labels.

What does claim 6 and 7 narrow about reduced dosing and schedule?

Claim 6: reduced daily dosage is “about 0.3 mg per day.”
Claim 7: reduced daily dosage is “about 0.15 mg per day,” administered as 0.3 mg once a day every other day.

These dependent claims are consistent with claim 1’s numeric options and make those dose levels a focal enforcement target.

What does claim 8 add about “concurrently administered” clarithromycin?

Claim 8: “The method of claim 1 wherein the clarithromycin is administered concurrently with the second colchicine daily dosage amount.”

This overlaps with the “within 1 to 2 days” timing definition in claim 1, but it also provides a potentially separate literal angle for “concurrency” language. The interplay between “within 1 to 2 days” and “concurrently” is that claim 8 likely captures the same conduct but may assist argumentation where exact “within 1 to 2 days” evidence is disputed.

Which treatment elements are mandatory for literal infringement under US 7,619,004?

A method must satisfy all mandatory elements of the asserted independent claim(s). For claim 1, those mandatory elements include:

Drug pairing: colchicine + clarithromycin in the same patient
Indication: prophylaxis of gout flares
Route: “orally administering” colchicine (explicit in claim 1)
Timing window: clarithromycin administration within 1 to 2 days of the reduced colchicine dosing
Dose reduction fraction: reduced colchicine daily dosage is a 75% reduction vs the specified baseline prophylactic colchicine daily dose used absent clarithromycin
Dose amounts: must match one of the enumerated baseline/reduced pairings (1.2→0.3 or 0.6→0.15, including every-other-day option where stated)

What is US 7,619,004’s practical “dose and timing” claim fence for competition?

US 7,619,004 is structured to fence off conduct where prescribers implement clarithromycin-colchicine management by a specific reduction.

How does the 75% reduction work as a legal threshold?

Claim 1 and claim 5 both make 75% reduction the defining threshold. In practice, this reads as:

If baseline daily colchicine prophylaxis is 1.2 mg/day, target daily reduced dose is 0.3 mg/day
If baseline daily prophylaxis is 0.6 mg/day, target reduced daily dose is 0.15 mg/day, including the regimen phrased as 0.3 mg every other day

Competitors attempting to avoid infringement would need to show either:

no concomitant clarithromycin within the defined timing window, or
reduced dosing that is not a 75% reduction from the claimed baseline anchor, or
dosing amounts not matching the claim’s enumerated dosage options.

How strict is the “within 1 to 2 days” timing requirement?

The claim’s definition of “concomitant administration” is temporal: clarithromycin within 1 to 2 days of administering the reduced colchicine dosage amount.

That means documentation tying the prescription and administration chronology to that time window is likely central in any dispute, particularly for “method-of-use” enforcement where a physician’s or pharmacy’s conduct must map to the claimed method.

What formulations and administration routes are implicated by the claims?

The claims focus on oral administration of colchicine. They do not claim formulation composition directly; they claim a method with dose schedules and tablet-based unit constraints in dependent claim 2.

Do the claims cover modified-release or non-tablet delivery systems?

Not expressly. The dependent claim 2 focuses on 0.6 mg colchicine tablet or half of a 0.6 mg colchicine tablet. If another delivery system avoids that unit, it may undercut dependent-claim literal coverage, but not necessarily independent claim 1 if dose amounts and timing are still met.

What does the patent landscape look like for this colchicine-clarithromycin safety interaction?

Based on the claim language alone, the patent targets a narrow safety management strategy that is likely to overlap with other documents in three lanes:

Labeling and clinical guidance for colchicine toxicity risk with macrolides (including clarithromycin).
Later-developed method claims for dose adjustment under specific drug-drug interactions.
Formulation and combination patents that are not necessarily implicated here because US 7,619,004 is not composition-based.

However, the request is specifically for “scope and claims and patent landscape” for US 7,619,004. Without bibliographic and legal status details (assignee, filing/publication dates, expiry, related family members, or prosecution history), a complete landscape across granted family members, continuations, and related Orange Book entries cannot be produced accurately.

Per the operating constraint, no partial or speculative landscape is provided beyond claim-scope implications.

How strong is the patent estate for US 7,619,004 based on claim specificity?

Strength drivers from the claim text:

Clear, numerically defined dosing targets (0.3 mg/day; 0.15 mg/day).
Clear baseline anchors (1.2 mg/day or 0.6 mg/day; “manufacturers’ recommended” in claim 5).
Clear temporal definition (within 1 to 2 days).
Clear route constraint (oral administration).

Strength limitation from claim text:

Narrowness: it is not “colchicine toxicity reduction with clarithromycin” broadly; it is that reduction through 75% dose reduction at defined dose values and timing.
It is method-of-use oriented: proof requires mapping real-world administration to the claimed steps.

What generic entry or biosimilar risks does US 7,619,004 create?

US 7,619,004 is a method-of-use patent over an existing small-molecule drug class. In practical terms, it primarily affects:

Prescribers’ and pharmacists’ ability to implement gout prophylaxis dosing in the presence of clarithromycin in a manner that matches the claims.
Generic/same-API manufacturers by creating a potential enforcement hook even after generic market entry, depending on how the method is practiced.

The claim is not a “new active ingredient” patent and not a formulation exclusivity patent. It operates by constraining a specific dosing strategy.

Key Takeaways

US 7,619,004 claims a specific method for colchicine gout flare prophylaxis in humans receiving clarithromycin, with mandatory elements including:
- oral administration
- clarithromycin within 1 to 2 days of reduced colchicine dosing
- 75% colchicine daily dose reduction relative to an explicit baseline
- explicit reduced doses of 0.3 mg/day (from 1.2 mg/day) or 0.15 mg/day (from 0.6 mg/day, including an every-other-day framing).
Dependent claims add constraints on:
- adult status (claim 3) and <70 years (claim 4)
- tablet unit form (0.6 mg tablet or half-tablet, claim 2)
- clarified dosing schedules around 0.3 mg/day and 0.15 mg/day regimens (claims 6–7)
- “concurrently” phrasing for clarithromycin (claim 8).
Enforceability and infringement mapping likely turn on documented dose fraction, dose amounts, and relative timing of clarithromycin and colchicine administration.

FAQs

Does US 7,619,004 require clarithromycin to be administered within exactly 1 to 2 days?

The claim defines concomitant administration as clarithromycin administration within 1 to 2 days of administering the reduced colchicine dosage amount.

Can a prescriber avoid infringement by reducing colchicine by less than 75%?

Literal claim coverage is tied to a 75% reduction, so reducing by a different fraction would generally fall outside the claim’s dose-reduction parameter.

Does the patent cover non-oral colchicine administration?

The claim language requires orally administering colchicine, so non-oral administration is outside the express method steps.

Is the tablet strength requirement in claim 2 mandatory for all infringement?

Claim 2 is dependent on claim 1, so it limits that dependent-claim coverage. Independent claim 1 focuses on dosage amounts and timing, not necessarily tablet unit form.

Is the claim limited to adults under 70?

Only the dependent claims 3 and 4 impose those limitations. Independent claim 1 is not limited by age, while claim 5 is restricted to adults.

References

US Patent 7,619,004 (claims as provided).

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Takeda Pharms Usa	COLCRYS	colchicine	TABLET;ORAL	022352-001	Jul 29, 2009		DISCN	Yes	No	⤷ Start Trial	⤷ Start Trial				METHOD OF USING COLCHICINE FOR THE PROPHYLAXIS OF GOUT FLARES	⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

Details for Patent: 7,619,004

Which drugs does patent 7,619,004 protect, and when does it expire?

Summary for Patent: 7,619,004